Navigation Links
Palomar Medical Technologies to Host Fourth Quarter and Year End 2011 Financial Results Conference Call and Webcast on February 9, 2012 at 11:30 AM Eastern Time
Date:1/26/2012

BURLINGTON, Mass., Jan. 26, 2012 /PRNewswire/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, will hold its quarterly conference call of its 2011 fourth quarter and year-end financial results on Thursday, February 9, 2012 at 11:30 AM Eastern Time. If you would like to participate, please call (877) 703-6107 at 11:20 AM Eastern Time on that day.

A live webcast of Palomar's conference call will be available in the Investor Relations' section of the Company's web site palomarmedical.com. The online archive will be available one hour after the call and continue through Thursday, February 16, 2012.

Palomar will also host a live webcast, including a slide presentation, to update analysts and investors on the PaloVia® Skin Renewing Laser® on Thursday, February 9, 2012 at 1:30 PM Eastern Time. If you would like to participate, please visit the About Palomar/Investors section of the Company's website at palomarmedical.com at 1:20 PM Eastern Time on that day.  The online archive of this webcast will be available one hour after the webcast concludes and will continue to be available through Thursday, February 16, 2012.

For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website.

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of laser- and light-based systems for aesthetic treatments.  Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology.

As a pioneer of fractional technology, Palomar is an owner of fundamental intellectual property in this area. In December 2009, Palomar received the first United States Food and Drug Administration (FDA) clearance for the treatment of stretch marks using a fractional non-ablative laser. In September 2010, Palomar received the first FDA clearance for a fractional ablative and fractional non-ablative combination treatment.

In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the FDA for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows these products to be marketed and sold directly to consumers without a prescription. Palomar introduced the PaloVia™ Skin Renewing Laser™ in December 2010.

There are now millions of laser- and light-based aesthetic procedures performed around the world every year in physician offices, clinics, spas, salons, and homes.  Palomar is testing many new and exciting applications to further advance the aesthetic market and other surgical applications.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2010 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 Contacts:Kerry McAnistan  

Investor Relations Assistant 

Palomar Medical Technologies, Inc.  

781-993-2411  

ir@palomarmedical.com


'/>"/>
SOURCE Palomar Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Palomar Medical Technologies to Host First Quarter 2011 Financial Results Conference Call and Webcast on April 28, 2011
2. CareFusion Selects Palomar Pomerado Health as Development Partner for Patient Safety Technologies
3. Palomar Medical Technologies to Host Fourth Quarter and Year End 2009 Financial Results Conference Call and Webcast on February 11, 2010
4. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
5. Varian Medical Systems Books $77 Million Order to Equip Proton Treatment Center in Saudi Arabia
6. Rochester Medical Reports Fiscal 2012 First Quarter Results
7. Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2012
8. Daniels Sharpsmart Presents Smarter Way to Manage Medical Waste
9. Canmedical Secures AsepticSure Distribution Rights For Canadian Veterinary Market
10. Leading Private Venture Capital Firms Invest $45 Million in Mevion Medical Systems
11. UH Case Medical Center the First in Region to Enroll Patients in Worldwide Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 The National University of ... data analytics company, signed a Memorandum of Understanding ... delivery in the region. Under ... Research and Technology (BIGHEART) at NUS and Holmusk ... related to healthcare IT and medical device development. ...
(Date:3/27/2017)... , March 27, 2017 ... specialty clinical-stage pharmaceutical company specializing in the development of ... public offering in the United States ... each ADS representing 40 ordinary shares of the ... In addition, Therapix has granted the underwriters a ...
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... The Radiology ... FRBMA, has begun to serve as its new executive director. Mr. Still was selected ... Search Committee. , “Bob, as he is known to our members, has been ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the United ... can be limited while the desire to conquer breakouts and eliminate skincare stress is ... every customer online, today released its inaugural survey on the State of Acne in ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... , ... With expansion and efficiency in mind, Patten Seed Company completed relocation ... plant opened in Marshallville in 2006, and a bagging and shipping facility has been ... of Patten Seed operations to the Middle Georgia location from their previous home in ...
(Date:3/28/2017)... ... ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A Prophets ... parents and teachers had asked of him that he had neglected to do, but this ... Almighty Creator. There were some who would have felt themselves to be special and better ...
Breaking Medicine News(10 mins):